Vir Biotechnology (NASDAQ: VIR) reports 66% undetectable HDV RNA with Phase 2 CHD combo

Investigational Monoclonal Antibody Shows Virologic Suppression in Chronic Hepatitis Delta

In Vir Biotechnology’s phase 2 Solstice study, 66% of participants with chronic hepatitis delta (CHD) receiving a monthly dose of combination tobevibart and elebsiran achieved undetectable hepatitis delta virus (HDV) RNA at Week 48.

Vir Biotechnology Announces AASLD The Liver Meeting® Presentation & New England Journal of Medicine Publication of Phase 2 Data Demonstrating Tobevibart & Elebsiran Combination Deliver High Rates of Undetectable HDV RNA with Favorable Safety Profile

SOLSTICE trial data demonstrate that 66% of chronic hepatitis delta participants receiving a monthly dose of tobevibart and elebsiran achieved undetectable HDV RNA at Week 48 Combination well-tolerated: No grade 3 or higher treatment-related adverse events and no treatment-related discontinuations ECLIPSE registrational program evaluating the combination of tobevibart and elebsiran for chronic hepatitis delta fully [...] The post Vir Biotechnolo…

Corrected: Phase 2 data from Vir’s hepatitis D combo regimen underscore market potential

New data from Vir Biotechnology’s chronic hepatitis D treatment reinforce the combo regimen’s promise of keeping viral levels low, as the company's pivotal trials advance ahead of schedule. Vir said Sunday evening that a monthly ...

Vir Biotechnology (NASDAQ: VIR) reports 66% undetectable HDV RNA with Phase 2 CHD combo

Phase 2 SOLSTICE: 66% (21/32) TND at Week 48; ~90% HBsAg